GGrantIndex
← Leaderboards

J. Silvio Gutkind

University Of California, San Diego

Google Scholar ↗PubMed ↗ORCID ↗
$14,229,551
Attributed
$26,226,310
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2017–25
$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$26,226,310 · 11

By mechanism

R01$15,725,988 · 7
U01$6,943,179 · 2
R25$2,097,977 · 1
R33$1,459,166 · 1

Top collaborators

Most similar at University Of California, San Diego

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsCellsCessation Of LifePathway InteractionsResponseMolecularSignal TransductionResistanceTumorMutationOncogenesDna Sequence AlterationBaseLesionFutureHead And Neck Squamous Cell CarcinomaImmuneNovel TherapeuticsPreventGenomicsMtor InhibitionDrug ResistanceFrap1 GeneEvent

Grant awards (67)

Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition$790,000
U01 · FY2025 · CA
Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral Cancer$585,606
R01 · FY2025 · DE · contact PI
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$522,110
R01 · FY2025 · CA · contact PI
Signal Transduction by PI3K/mTOR$483,480
R01 · FY2025 · DE
Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer$483,360
R01 · FY2025 · DE · contact PI
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$475,111
R01 · FY2025 · DE · contact PI
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition$750,499
U01 · FY2024 · CA
Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral Cancer$595,600
R01 · FY2024 · DE · contact PI
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$502,859
R01 · FY2024 · CA · contact PI
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$474,976
R01 · FY2024 · CA · contact PI
Signal Transduction by PI3K/mTOR$473,810
R01 · FY2024 · DE
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$465,609
R01 · FY2024 · DE · contact PI
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition$790,000
U01 · FY2023 · CA
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$525,822
R01 · FY2023 · CA · contact PI
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$489,974
R01 · FY2023 · CA · contact PI
Signal Transduction by PI3K/mTOR$483,480
R01 · FY2023 · DE
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$475,111
R01 · FY2023 · DE · contact PI
Multidisciplinary Educational Approach to Reducing Cancer Disparities$352,007
R25 · FY2023 · CA · contact PI
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers$838,091
U01 · FY2022 · DE
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$535,362
R01 · FY2022 · CA · contact PI
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$489,974
R01 · FY2022 · CA · contact PI
Signal Transduction by PI3K/mTOR$478,645
R01 · FY2022 · DE
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$475,111
R01 · FY2022 · DE · contact PI
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy$462,426
R01 · FY2022 · DE · contact PI
Multidisciplinary Educational Approach to Reducing Cancer Disparities$459,446
R25 · FY2022 · CA · contact PI
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers$849,319
U01 · FY2021 · DE
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$565,730
R01 · FY2021 · CA · contact PI
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$499,263
R01 · FY2021 · CA · contact PI
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$491,893
R01 · FY2021 · DE · contact PI
Signal Transduction by PI3K/mTOR$483,098
R01 · FY2021 · DE
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy$467,098
R01 · FY2021 · DE · contact PI
Multidisciplinary Educational Approach to Reducing Cancer Disparities$345,986
R25 · FY2021 · CA · contact PI
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers$827,143
U01 · FY2020 · DE
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC$513,131
R01 · FY2020 · CA · contact PI
Multidisciplinary Educational Approach to Reducing Cancer Disparities$469,075
R25 · FY2020 · CA · contact PI
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy$465,921
R01 · FY2020 · DE · contact PI
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$441,893
R01 · FY2020 · DE · contact PI
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers$366,000
U01 · FY2020 · DE
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$50,000
R01 · FY2020 · DE · contact PI
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers$852,739
U01 · FY2019 · DE
Multidisciplinary Educational Approach to Reducing Cancer Disparities$471,463
R25 · FY2019 · CA · contact PI
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy$465,473
R01 · FY2019 · DE · contact PI
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$441,893
R01 · FY2019 · DE · contact PI
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers$879,388
U01 · FY2018 · DE
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy$478,383
R01 · FY2018 · DE · contact PI
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$441,893
R01 · FY2018 · DE · contact PI
Area C: Genome-wide identification and targeting of resistance to cancer therapy$1,242,934
R33 · FY2017 · CA · contact PI
Targeting Signaling Vulnerabilities for Oral Cancer Prevention$441,893
R01 · FY2017 · DE · contact PI
Area C: Genome-wide identification and targeting of resistance to cancer therapy$216,232
R33 · FY2017 · CA
Oral Carcinogenesis$1,349,334
ZIA · FY2015 · DE · contact PI
Molecular Mechanisms Of Growth Control And Carcinogenesis$1,349,334
ZIA · FY2015 · DE · contact PI
Oral Carcinogenesis$1,805,309
ZIA · FY2014 · DE · contact PI
Molecular Mechanisms Of Growth Control And Carcinogenesis$1,805,309
ZIA · FY2014 · DE · contact PI
Oral Carcinogenesis$0
Z01 · FY2006 · DE · contact PI
Molecular Mechanisms Of Growth Control And Carcinogenesi$0
Z01 · FY2006 · DE · contact PI
Oral Carcinogenesis$0
Z01 · FY2005 · DE
Molecular Mechanisms Of Growth Control/Carcinogenesis$0
Z01 · FY2005 · DE
Molecular Mechanisms Of Growth Control And Carcinogenesi$0
Z01 · FY2004 · DE
Oral Carcinogenesis$0
Z01 · FY2004 · DE
Oral Carcinogenesis$0
Z01 · FY2003 · DE
Molecular Mechanisms Of Growth Control And Carcinogenesi$0
Z01 · FY2003 · DE
Oral Carcinogenesis$0
Z01 · FY2002 · DE
Molecular Mechanisms Of Growth Control And Carcinogenesi$0
Z01 · FY2002 · DE
Oral Carcinogenesis$0
Z01 · FY2001 · DE
Molecular Mechanism Of Growth Control And Carcinogenesis$0
Z01 · FY2001 · DE
Molecular Mechanisms of Growth Control and Carcinogenesis$0
Z01 · FY2000 · DE
Oral Carcinogenesis$0
Z01 · FY2000 · DE